Farnaz Zahedifard

Farnaz Zahedifard

UNVERIFIED PROFILE

Are you Farnaz Zahedifard?   Register this Author

Register author
Farnaz Zahedifard

Farnaz Zahedifard

Publications by authors named "Farnaz Zahedifard"

Are you Farnaz Zahedifard?   Register this Author

37Publications

377Reads

24Profile Views

Comparative study of different forms of Jellein antimicrobial peptide on Leishmania parasite.

Exp Parasitol 2020 Feb 17;209:107823. Epub 2019 Dec 17.

Immunotherapy and Leishmania Vaccine Research Department, Pasteur Institute of Iran, Tehran, Iran. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2019.107823DOI Listing
February 2020

Antileishmanial effect of rapamycin as an alternative approach to control Leishmania tropica infection.

Vet Parasitol 2019 Dec 10;276:108976. Epub 2019 Nov 10.

Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetpar.2019.108976DOI Listing
December 2019

Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials.

PLoS Negl Trop Dis 2019 02 27;13(2):e0007217. Epub 2019 Feb 27.

Immunotherapy and Leishmania Vaccine Research Department, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0007217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411200PMC
February 2019

Prospects for antimicrobial peptide-based immunotherapy approaches in Leishmania control.

Expert Rev Anti Infect Ther 2018 06 12;16(6):461-469. Epub 2018 Jun 12.

a Department of Immunotherapy and Leishmania Vaccine Research , Pasteur Institute of Iran , Tehran , Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14787210.2018.1483720DOI Listing
June 2018

Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice.

PLoS Negl Trop Dis 2017 12 18;11(12):e0006123. Epub 2017 Dec 18.

Department of Immunotherapy and Leishmania Vaccine Research, Pasteur institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0006123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749894PMC
December 2017

Live Leishmania tarentolae secreting HNP1 as an immunotherapeutic tool against Leishmania infection in BALB/c mice.

Immunotherapy 2017 10;9(13):1089-1102

Department of Immunotherapy & Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran, 13194.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0076DOI Listing
October 2017

Delivery systems for Leishmania vaccine development.

Expert Rev Vaccines 2016 07 28;15(7):879-95. Epub 2016 Mar 28.

a Department of Immunotherapy and Leishmania Vaccine Research , Pasteur Institute of Iran , Tehran , Iran (the Islamic Republic of).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14760584.2016.1157478DOI Listing
July 2016

Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy.

J Breast Cancer 2016 Mar 25;19(1):34-44. Epub 2016 Mar 25.

Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4048/jbc.2016.19.1.34DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822105PMC
March 2016

Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis.

Vet Parasitol 2015 Sep 21;212(3-4):130-9. Epub 2015 Jul 21.

Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, 69, Pasteur Ave., Tehran 13164, Iran. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetpar.2015.07.005DOI Listing
September 2015

Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections.

Mol Immunol 2013 Jan 25;53(1-2):149-60. Epub 2012 Aug 25.

Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molimm.2012.07.011DOI Listing
January 2013

Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.

Immunol Lett 2012 Dec 17;148(2):117-25. Epub 2012 Oct 17.

Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016524781200215
Publisher Site
http://dx.doi.org/10.1016/j.imlet.2012.10.003DOI Listing
December 2012

Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.

Immunotherapy 2012 Nov;4(11):1107-20

Molecular Immunology & Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.12.110DOI Listing
November 2012

Therapeutic live vaccines as a potential anticancer strategy.

Int J Cancer 2012 Oct 20;131(8):1733-43. Epub 2012 Jun 20.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.27640DOI Listing
October 2012

Effect of A2 gene on infectivity of the nonpathogenic parasite Leishmania tarentolae.

Parasitol Res 2011 Sep 26;109(3):793-9. Epub 2011 Mar 26.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00436-011-2325-4DOI Listing
September 2011

Leishmania major: Protective capacity of DNA vaccine using amastin fused to HSV-1 VP22 and EGFP in BALB/c mice model.

Exp Parasitol 2011 May 26;128(1):9-17. Epub 2011 Jan 26.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, 69 Pasteur Ave., Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2011.01.012DOI Listing
May 2011

Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.

Exp Parasitol 2011 Mar 25;127(3):627-36. Epub 2010 Dec 25.

Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2010.12.007DOI Listing
March 2011

Leishmania major: disruption of signal peptidase type I and its consequences on survival, growth and infectivity.

Exp Parasitol 2010 Oct 22;126(2):135-45. Epub 2010 Apr 22.

Molecular Immunology and Vaccine Research Lab, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2010.04.009DOI Listing
October 2010

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

Vaccine 2009 Dec 8;28(1):53-62. Epub 2009 Oct 8.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.09.114DOI Listing
December 2009

Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.

Indian J Med Res 2009 Nov;130(5):533-41

Molecular Immunology & Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
November 2009

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.

Vaccine 2008 Oct 18;26(46):5822-9. Epub 2008 Sep 18.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2008.08.065DOI Listing
October 2008

Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.

Vaccine 2008 Jun 18;26(26):3362-70. Epub 2008 Apr 18.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2008.03.082DOI Listing
June 2008

Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice.

Exp Parasitol 2008 Mar 13;118(3):393-401. Epub 2007 Oct 13.

Molecular Immunology and Vaccine Research Laboratory, Pasteur Institute of Iran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exppara.2007.10.004DOI Listing
March 2008

Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy.

J Biotechnol 2006 Jul 3;124(3):602-14. Epub 2006 Mar 3.

Department of Biotechnology, Faculty of Science, University of Tehran, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2006.01.014DOI Listing
July 2006

Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.

Vaccine 2006 Apr 25;24(16):3290-7. Epub 2006 Jan 25.

Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, P.O. Box 11365-6699, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2006.01.030DOI Listing
April 2006

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.

Vaccine 2006 Mar 16;24(12):2169-75. Epub 2005 Nov 16.

Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, P.O. Box 11365-6699, Tehran, Iran.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S0264410X0501139
Publisher Site
http://dx.doi.org/10.1016/j.vaccine.2005.11.011DOI Listing
March 2006